 |
 Takeover Mania Sweeping Biotech Sector by Robert Morris, Editor Biotech stocks are off to a fast start in 2012. After gaining just 6.9% last year, the cutting-edge industry is up 17.7% year-to-date. That's eye-popping performance no matter how you slice it. To put this in perspective, you need only look at the year-to-date performance of the major market indices. The Dow Jones Industrials are up just 5.3% so far this year. The S&P 500 is slightly better with gains of 6.9%. And the Nasdaq Composite is 11.5% higher. -------------Sponsor------------- Currencies are risky and you need a lot of money to invest in them, right? WRONG! Our own in-house currency expert, Karl Stevenson, can show you the secrets to making insane amounts of money from the movement of the world's currencies. And forget about unlimited risk, spending all day in front of a computer, and having tons of money to start with... Karl can show you how to easily and safely take $2,000 and turn it into $75,410 or more... over and over again! Click here to find out how... ------------------------------------ No question about it, biotech stocks are on fire! Why are investors going gaga over biotech? The answer is fairly simple. The industry is benefiting from a number of highly publicized and lucrative takeovers. According to MarketWatch, a whopping $6.2 billion in acquisitions were announced in the first month of 2012. Here are a few of the larger, recently announced takeovers... Bristol-Myers Squibb (BMY) is acquiring hepatitis C drug developer Inhibitex (INHX) for $2.5 billion. Amgen (AMGN) has agreed to purchase Micromet (MITI) and their new class of cancer drug candidates for $1.2 billion. And Celgene (CELG) is acquiring privately owned Avila Therapeutics in a deal valued up to $925 million. As you might imagine, these acquisitions have generated huge profits for investors in the target companies. For example, INHX soared 140% on news of their acquisition by BMY.  And while MITI increased by just 32% on their news, the stock is up 163% from the early September low.  But it's not just the target companies that are soaring. Several other biotech stocks are moving higher on the acquisition news as well. You see, biotech investors follow a familiar pattern when takeovers are announced. They tend to pile into stocks of other biotechs developing drugs similar to those of the acquisition target. Take INHX for example... They're developing a next generation drug for hepatitis C virus (HCV). News of INHX's acquisition drew attention to the huge market opportunity in this disease area. Several analysts project the HCV market will hit a whopping $20 billion by 2020. As a result, investors have been snapping up shares of other biotechs who are also developing drugs for HCV. Idenix Pharmaceuticals (IDIX) surged from $7.05 to a recent high of $15.25 a share. That was a stellar 116% gain in just eight trading days.  Not too shabby! Another example is Achillion Pharmaceuticals (ACHN). This biotech is also developing a next generation treatment for HCV. And until recently, it was a primary holding in my Biotech Supertrader service. These shares soared 64% in the days following the news of BMY's acquisition of INHX.  That's a terrific short-term gain to be sure. But my subscribers did even better... You see, I recommended buying ACHN back in early August when the stock was trading at $5.51 per share. After the stock popped on the INHX acquisition news, I told my subscribers to sell half their shares for a sensational 116% profit. And then a few days later, I recommended selling the remaining shares to lock in gains of 93%. That works out to an average return of 105% on the whole position. Not a bad profit in just five months' time! No question about it, you can make big money trading the biotech takeover mania. All you need to do is keep an eye out for news of biotech acquisitions. When one is announced, buy shares of other biotechs who are developing similar drugs. Before you know it, you'll be raking in the profits. Profitably Yours, Robert Morris | Monday, February 6, 2012  • Sturm Ruger (RGR) hit a new 52-week high of $43.06. The company's market cap is now just over $816 million. • Alnylam Pharmaceuticals (ALNY) set a new 52-week high of $13.23. They now have a market cap of over $555 million. • Abercrombie & Fitch (ANF) fell to a new 52-week low of $40.25. Their market cap is now under $3.5 billion.  "There are two kinds of companies, those that work to charge more and those that work to charge less. We will be the second." -Jeff Bezos   
 Does A Golden Cross Really Mean It's Time To Buy Stocks? Friday, February 3, 2012 Shorting Netflix Wednesday, February 1, 2012 Avoid This Sector In 2012 Monday, January 30, 2012    |
 Copyright 2012 Hyperion Financial Group, LLC. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This email may only be used pursuant to the subscription agreement controlling use of the Dynamic Wealth Report website and any reproduction, copying, or redistribution of this email or its contents, in whole or in part, is strictly prohibited without the express written permission of Hyperion Financial Group, LLC. LEGAL DISCLAIMER: Neither Hyperion Financial Group LLC nor any of its employees are a registered investment advisor or a Broker/Dealer. As such, Hyperion Financial Group, LLC does not offer or provide personalized investment advice. Although Hyperion Financial Group, LLC employees may answer general customer service questions, they are not licensed under securities laws to address your particular investment situation. Nothing in this report, nor any communication by our employees to you should be considered personalized investment advice. Owners and writers may have positions in the securities that are discussed. However, no associated employees may intentionally engage in any transaction that directly or indirectly competes with the interests of our subscribers. We accept no compensation from any companies mentioned in our reports. Past performance is no guarantee of future results. All information is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell any security. All opinions, analyses and information contained herein are based on sources believed to be reliable and written in good faith, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. Investments recommended in this publication should only be made after consulting with your financial advisor. Any brokers mentioned herein constitute a partial list of available brokers and is for your information only. We do not recommend or endorse any brokers, dealers, or investment advisors. |
| This message was sent to ignoble.experiment@arconati.us from: Hyperion Financial | 20701 N Scottsdale Rd, Ste 107-154 | Scottsdale, AZ 85255 | Email Marketing by |
| Manage Your Subscription | Forward To a Friend |
No comments:
Post a Comment
Keep a civil tongue.